This would be a good update for the therapeutics manuscript:
The U.S. health regulator revised on Monday the emergency use authorizations for COVID-19 antibody treatments from Regeneron (REGN.O) and Eli Lilly (LLY.N) to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.
This would be a good update for the therapeutics manuscript:
From https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-restrict-use-regeneron-lilly-covid-antibody-drugs-wapo-2022-01-24/